Jaguar Health (JAGX) Non-Current Deffered Revenue (2015 - 2026)
Jaguar Health's (JAGX) quarterly Non-Current Deffered Revenue came in at $340000.0 in Q1 2026, down 33.33% year-on-year from $510000.0 in Q1 2025, and down 10.99% on a QoQ basis from $382000.0 in Q4 2025.
Jaguar Health (JAGX) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 6 years of Non-Current Deffered Revenue data on file, last reported at $340000.0 in Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 33.33% year-over-year to $340000.0 in Q1 2026; TTM through Mar 2026 was $340000.0, a 33.33% decrease from a year earlier, with the FY2025 full-year figure at $382000.0, down 30.92% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $340000.0, down from $382000.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for JAGX reached as high as $680000.0 in Q1 2024 and fell as low as $340000.0 in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $510111.1 across 3 years, with a median of $510000.0 in 2025.
- Across the five-year window, Non-Current Deffered Revenue retreated 25.0% in 2025 and slumped 33.33% in 2026, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $553000.0 in 2024, then tumbled by 30.92% to $382000.0 in 2025, then slipped by 10.99% to $340000.0 in 2026.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $340000.0 in Q1 2026, $382000.0 in Q4 2025, and $425000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,774.59 Bn | 1,774.53 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn | - |
| 4 | Vertex Pharmaceuticals | 123.91 Bn | 116.66 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 71.79 Bn | 63.04 Bn | 3.31 Bn | 225.10 Mn |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - | - |
| 7 | Argenx Se | 54.75 Bn | 49.57 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.10 Bn | 35.10 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.11 Bn | 36.11 Bn | - | - |
| 10 | Jaguar Health | 509,443.80 | -9.55 Mn | 19.11 Mn | 340,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | 553,000.00 |
| Sep 30, 2024 | 595,000.00 |
| Jun 30, 2024 | 638,000.00 |
| Mar 31, 2024 | 680,000.00 |
| Jun 30, 2017 | 7,271.00 |
| Mar 31, 2017 | 7,114.00 |
| Dec 31, 2016 | 6,956.00 |
| Sep 30, 2016 | 6,799.00 |
| Jun 30, 2016 | 6,642.00 |
| Mar 31, 2016 | 4,981.00 |
| Dec 31, 2015 | 3,321.00 |
| Sep 30, 2015 | 1,660.00 |